Page 5 of 19: studies 81 to 100 of 375, newest first. Back to the psilocybin overview
Evidence-Based Practice October 19, 2023 Lucia Carbajal, Tessa E. Moore, R. H. Barry Sample et al.
Carbajal, Lucia MD; Moore, Tessa MD; Sample, Reise MD; Nelson, Joseph MD Author Information
Religions October 19, 2023 Brian Claude Macallan 3 citations
This paper explores Christian responses to religious and spiritual experiences (RSEs) associated with psilocybin-assisted therapy (PAT). It addresses the challenges of defining and understanding spiritual and religious experiences and examines the theological implications of PAT-induced RSEs. It highlights the growing acceptance of PAT as a therapeutic approach and its potential benefits for...
Psychopharmacology October 19, 2023 Arya Rahbarnia, Zhaoxia Li, Paul J Fletcher 9 citations
Neuropsychiatric disorders such as depression are characterized in part by attention deficits. Attention is modulated by the serotonin (5-HT) neurotransmitter system. The 5-HT2A agonist and hallucinogen psilocybin (PSI) is a promising treatment for disorders characterized by attention changes. However, few studies have investigated PSI's direct effect on attention. Using the rodent continuous...
Journal of Psychopharmacology October 16, 2023 Maciej Koniewski, Piotr Popik, Natalia Malikowska‐racia et al. 6 citations
Background: In clinical studies, psychedelics including psilocybin and D-lysergic acid diethylamide (LSD) demonstrate rapid and persistent antidepressant effects. Since the effective treatment with psychedelics is usually provided with psychotherapy, it is debatable whether their prolonged efficacy can be observed in infrahuman species. Preclinical reports on psychedelics’ effects most often...
Clinical Psychopharmacology and Neuroscience October 16, 2023 Tessa Watford, Naqash Masood 21 citations
Psilocybin is a classical psychedelic which has been utilised for healing purposes for millenia. However, with its classification as a Schedule I substance, research into this compound is scarce with few FDA-approved clinical studies. Despite this, profound findings into its antidepressant effects (largely through its action on 5-HT1a receptors) in mental illnesses such as major depressive...
Scientific Reports October 14, 2023 Nathalie M. Rieser, Ladina P Gubser, Flora Moujaes et al. 14 citations
Research into the use of psilocybin for the treatment of psychiatric disorders is a growing field. Nevertheless, robust brain-behavior relationships linking psilocybin-induced brain changes to subjective drug-induced effects have not been established. Furthermore, it is unclear if the acute neural effects are dependent on individual heterogeneity in baseline characteristics. To address this, we...
Research Directions Depression October 13, 2023 Ian B. Hickie, F. Markus Leweke, Allan H. Young 1 citation
In recent years, there has been considerable enthusiasm among research groups focused on developing novel therapies for treatment-resistant depression, and a wider community that has had experiences using recreational drugs, in more systematic evaluation of the therapeutic value of these compounds (Goodwin et al., 2022; Young, 2023). This has also been associated with advocacy for...
BCIT Environmental Public Health Journal October 12, 2023 Payman Baharmand, Amardeep Kambo
Psilocybin is a naturally occurring hallucinogen found in different species of fungi. Psilocybin has gained extensive social popularity and political attention in the United States. Research has shown that psilocybin and psychological therapy may have promising therapeutic applications for safer and more effective treatment of mental illnesses such as major depressive disorder, addiction,...
October 11, 2023 Stefanie Enriquez‐geppert, Jaroslav Krc, Fiachra O'Higgins et al. 1 citation preprint
Executive function deficits, common in psychiatric disorders, hinder daily activities and may be linked to diminished neural plasticity, affecting treatment and training responsiveness. In this pioneering study, we evaluated the feasibility and preliminary efficacy of psilocybin-assisted frontal-midline theta neurofeedback (NF), a neuromodulation technique leveraging neuroplasticity, to improve...
Georgetown Scientific Research Journal October 10, 2023 Anna Douglas, Daniel Staas, Anna Hampton et al. 1 citation
Depression remains one the most commonly diagnosed mental health disorders in the United States. The Food and Drug Administration granted psilocybin breakthrough therapy status four years ago as a possible solution to this pervasive disorder. Since then, psilocybin, and hallucinogens in general, have produced promising results as alternatives to classical antidepressants. As more research...
Journal of Psychoactive Drugs October 10, 2023 Ashmita Grewal, Kalysha Closson, Gina Martin et al. 11 citations
Survivors of adverse childhood experience are at elevated risk for psychological distress. In recent years, renewed interest in psychedelic medicine has highlighted the therapeutic potential of psilocybin for those who have experienced childhood adversity. However, recreational psilocybin use remains illegal and access to approved therapies is difficult. Such use provides an opportunity to...
Clinical Pharmacology & Therapeutics October 5, 2023 Robert H. Dworkin, Michael P McDermott, Sandeep M. Nayak et al. 16 citations
Clinical trials of psychedelics have provided support for their potential efficacy and safety.Although most combined a psychedelic with psychological support akin to psychotherapy, providing psychotherapy is costlier and more difficult to scale than providing only support to reduce harms.Trials with factorial designs can evaluate the individual effects of a psychedelic and psychotherapy and any...
The Brown University Psychopharmacology Update October 4, 2023
Ongoing antidepressant treatment is believed to alter the psychedelic effect of psilocybin, so most psilocybin trials have required withdrawal from antidepressants before enrollment. There has been recent evidence, however, that administration of a selective serotonin reuptake inhibitor (SSRI) does not significantly alter the acute subjective effects of psilocybin. A Phase 2 open-label trial...
Expert Opinion on Investigational Drugs October 3, 2023 Zofia Kozak, Matthew W Johnson, Scott T Aaronson 10 citations
There is still much unknown regarding the risks of psilocybin treatment. When weighing the known risks and benefits of psilocybin treatment against those found in existing standards of care, among patients with depression, patients with treatment-resistant depression (TRD) may be the most suitable candidates for psilocybin treatment at this time.
Expert Opinion on Emerging Drugs October 2, 2023 Katarzyna Śladowska, Paweł Kawalec, Tomasz Brzostek et al. 4 citations
Clinical phase I-II trials published to date reported promising results for psilocybin in the treatment of patients with major depressive disorder and treatment-resistant depression, in a relatively short time after administration. However, before psilocybin is approved for use and administered to patients with depression, the results of large ongoing phase III clinical trials are needed to...
Frontiers in Pharmacology October 2, 2023 Victor P Acero, Emily S Cribas, Kevin D Browne et al. 20 citations
There has recently been a resurgence of interest in psychedelic compounds based on studies demonstrating their potential therapeutic applications in treating post-traumatic stress disorder, substance abuse disorders, and treatment-resistant depression. Despite promising efficacy observed in some clinical trials, the full range of biological effects and mechanism(s) of action of these compounds...
IBRO Neuroscience Reports October 1, 2023 Chloé Galipeau, Miguel Farinha‐ferreira, Jean-Charles Rene’ Pasquin Mariani et al.
Psilocybin is a 5-HT2AR agonist, responsible for the psychoactive effects of psychedelic mushrooms, which has recently shown therapeutic potential for several conditions, including major depressive disorder. However, the mechanisms underlying this effect, and the possibility of dissociating the psychedelic and antidepressant actions of psilocybin, remain undetermined, with preclinical research...
IBRO Neuroscience Reports October 1, 2023 Ines Erkizia-Santamaría, J. Javier Meana, Igor Horrillo et al.
Long-term exposure to stress is associated to HPA axis alterations and the development of depression. Chronic unpredictable mild stress (CUMS) is a widely used and validated animal model of depression, and presents phenotypic features of this disease, like anhedonia and despair, along with physiological and neurochemical alterations. Recently, the psychedelic 5-HT2A agonist psilocybin has...
IBRO Neuroscience Reports October 1, 2023 Čestmír Vejmola, Kateřina Syrová, Klára Šíchová et al.
GABAB receptors are the metabotropic GABA neurotransmitter receptors in the central nervous system constituting a fundamental part of the inhibitory modulation mechanism.These receptors are heterodimers composed of GABAB1 and GABAB2 which function is modulated by the potassium channel tetramerization domain proteins (KCTD) from clade F (KCTD16; KCTD12 and KCTD8).In our experiments we explored...
Journal of Palliative Medicine October 1, 2023 Noah D Gold, Austin J. Mallard, Jacob C Hermann et al. 5 citations
Background: Amyotrophic lateral sclerosis (ALS) is an aggressive, terminal neurodegenerative disease that causes death of motor neurons and has an average survival time of 3-4 years. ALS is the most common motor neuron degenerative disease and is increasing in prevalence. There is a pressing need for more effective ALS treatments as available pharmacotherapies do not reverse disease progression...